Data From Thirteen Studies Highlighting AdvanDx, Inc.'s Infectious Disease Assays To Be Presented At The 114th General Meeting Of The American Society of Microbiology (ASM)

WOBURN, Mass., May 16, 2014 /PRNewswire/ -- AdvanDx, Inc., a leading provider of molecular diagnostic tests for the rapid identification of bloodstream infections, announced today that data from thirteen studies will be presented at the 114^th General Meeting for the American Society for Microbiology beginning on May 17 in Boston, Massachusetts.

Four of the studies will present data on mecA XpressFISH (FDA clearance pending), a novel method for the rapid detection of methicillin-resistant Staphylococcusaureus (MRSA) from positive blood cultures. AdvanDx recently submitted its mecA XpressFISH assay to the U.S. Food and Drug Administration for 510(k) clearance.

In addition, five studies will present data on the Company’s QuickFISH products: Staphylococcus QuickFISH (FDA cleared; CE-IVD); Enterococcus QuickFISH (FDA cleared; CE-IVD); Gram-Negative QuickFISH (FDA cleared; CE-IVD); andQuickFISH Candida (CE-IVD).

“We’re excited about the large number of studies being presented on our assays at the 2014 General Meeting of ASM, the world’s largest meeting for microbiologists,” says Dennis Langer, M.D., CEO of AdvanDx. “The studies highlight the accuracy, speed and reliability of our rapid diagnostics for the identification of life-threating bloodstream infections. We remain committed to our mission to develop innovative products that help clinicians improve patient outcomes and reduce overall healthcare costs.”

The following posters will be presented at ASM:

1. Poster 97: “Automated PNA Gram Stained Smears, Reading, Images Acquisition and Storage on the WASPlab Patient Data Log Are Facilitating the Microbiology Workflow.”
   (Sunday, May 18^th, 10:45-12:00)
2. Poster 677: “Multicenter Evaluation of Candida QuickFISH BC for Identification of Candida Species Directly from Blood Culture Bottles.” (Sunday, May 18, 12:30-1:45)
3. Poster 1143: “Charcoal-Containing Blood Culture Bottles Are Suitable Specimens for Rapid Pathogen Identification Using AdvanDx QuickFISH BC Assay (Monday, May 19, 10:45-12:00)
4. Poster 1148: “Controlled Clinical Laboratory Comparison of QuickFISH and FilmArray BCID Panel for Identification of Microorganisms in New BacT/ALERT FA Plus Blood Culture Bottles.”
5. Poster 1149: “Comparison of MALDI-TOF Mass Spectrometry and Staphylococcus QuickFISH BC for the Discrimination of Staphylococcus aureus from Coagulase-Negative Staphylococci Directly from Positive Blood Cultures.”
6. Poster 1151: “Rapid Identification of Methicillin-Resistant S. aureus by mecA XpressFISH.”
7. Poster 1082: “Antimicrobial Stewardship and Therapeutic Outcomes of Patients with Staphylococcus aureus Bacteremia Detected by Conventional Culture Methods.”
8. Poster 1585: “Identification of Bacteria Directly from Positive Blood Cultures by MS PNA ID.”
   (Monday, May 19, 12:30-1:45)
9. Poster 2027: “Comparison of the AdvanDx Gram-Negative QuickFISH BC and MALDI-TOF Mass Spectrometry for Identification of Gram-Negative Rods from Positive Blood Cultures.”
   (Tuesday, May 20^th, 10:45-12:00)
10. Poster 2039: “Significant Reduction in Length of Stay After Implementing Rapid PNA-FISH Testing.”
11. Poster 2049: “A Multicenter Evaluation of StaphylococcusQuickFISH BC and mecA XpressFISH for Rapid Identification of Methicillin-Resistant Staphylococcus aureus (MRSA) from Positive Blood Culture Bottles.”
12. Poster 2547: “mecA mRNA Expression in Heterogeneous and Homogeneous Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Determined by mecA XpressFISH Assay.”
    (Tuesday, May 20^th, 12:30-1:45)
13. Poster 2551: “Rapid Detection and Identification of Methicillin-Resistant and Methicillin-Sensitive Staphylococcal Bacteremia in Blood Culture”

About AdvanDx

AdvanDx, Inc. is a leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx’s easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

For more information visit www.AdvanDx.com.

PN2418A

SOURCE AdvanDx, Inc.